• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Postma Robert W was granted 5,142 shares, increasing direct ownership by 16% to 38,250 units (SEC Form 4)

    11/26/25 9:26:18 PM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TCRT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Postma Robert W

    (Last) (First) (Middle)
    C/O ALAUNOS THERAPEUTICS, INC.
    501 E. LAS OLAS BLVD. SUITE 300

    (Street)
    FORT LAUDERDALE FL 33301

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Alaunos Therapeutics, Inc. [ TCRT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    11/21/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/21/2025 A 5,142(1) A $3.16 38,250 D
    Common Stock 13 I By spouse's IRA
    Common Stock 33,333(2) I By WaterMill Asset Management Corp.(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents shares of common stock issued in lieu of board fees.
    2. The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill.
    /s/ Postma, Robert W 11/26/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TCRT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TCRT

    DatePrice TargetRatingAnalyst
    10/4/2022$3.00Overweight
    Wells Fargo
    More analyst ratings

    $TCRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Weis Holger was granted 3,700 shares, increasing direct ownership by 306% to 4,911 units (SEC Form 4)

    4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)

    5/27/26 4:33:30 PM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Vieser Jaime was granted 6,515 shares, increasing direct ownership by 20% to 38,853 units (SEC Form 4)

    4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)

    5/1/26 4:30:59 PM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Postma Robert W was granted 6,274 shares, increasing direct ownership by 14% to 50,146 units (SEC Form 4)

    4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)

    5/1/26 4:18:01 PM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TCRT
    SEC Filings

    View All

    Alaunos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)

    5/26/26 11:00:21 AM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alaunos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)

    5/18/26 8:00:43 AM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Alaunos Therapeutics Inc.

    10-Q - Alaunos Therapeutics, Inc. (0001107421) (Filer)

    5/15/26 5:29:30 PM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TCRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo resumed coverage on Alaunos Therapeutics with a new price target

    Wells Fargo resumed coverage of Alaunos Therapeutics with a rating of Overweight and set a new price target of $3.00

    10/4/22 7:18:05 AM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TCRT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

    ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese miceA non-confidential investor presentation summarizing the preclinical dataset is now available FORT LAUDERDALE, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (NASDAQ:TCRT) today reported an integrated preclinical readout for ALN1003, the Company's investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders. The readout consolidates findings from two non-Good Laborato

    5/26/26 11:01:00 AM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

    FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (NASDAQ:TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's investigational oral metabolic therapeutic candidate. Across selected biomarker and liver histology assessments, ALN1003 showed effects on insulin-resistance-related measures, adipose endocrine markers, and qualitative liver pathology findings relevant to metabolic syndrome biology. These findings support continued preclinical development of ALN1003 in metabolic syndrome and related conditions, including obesity, metabolic dysfunction-associated steatotic liver diseas

    5/18/26 8:00:00 AM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Valion Bio Appoints Melinda Lackey as General Counsel

    Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership TeamSAN ANTONIO, May 4, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (NASDAQ:VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute Radiation Syndrome (ARS) and oncology supportive care, today announced the appointment of Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs. Ms. Lackey brings nearly two decades of combined scientific and legal experience across clinical-stage biopharmaceutical development, intellectual property strategy, and Nasdaq public company governance, a profile built f

    5/4/26 4:05:00 PM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TCRT
    Leadership Updates

    Live Leadership Updates

    View All

    Valion Bio Appoints Melinda Lackey as General Counsel

    Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership TeamSAN ANTONIO, May 4, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (NASDAQ:VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute Radiation Syndrome (ARS) and oncology supportive care, today announced the appointment of Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs. Ms. Lackey brings nearly two decades of combined scientific and legal experience across clinical-stage biopharmaceutical development, intellectual property strategy, and Nasdaq public company governance, a profile built f

    5/4/26 4:05:00 PM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors

    HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced the appointment of Robert J. Hofmeister, PhD, MS, Chief Scientific Officer of a stealth early stage biotechnology company, to the Company's Board of Directors, effective immediately. Dr. Hofmeister will replace Chris Bowden, MD. "We extend our gratitude to Chris for his invaluable contributions to Alaunos during his tenure, and welcome Robert to the Alaunos Board," said Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. "Robert bring

    3/30/23 7:00:40 AM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations

    HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, today announced the appointment of Abhishek Srivastava, Ph.D. as Vice President of Technical Operations. Dr. Srivastava will lead the Company's manufacturing operations, including overseeing process optimization and capacity expansion. "Abhi brings extensive experience in cell therapy technical operations, and I am pleased to welcome him to our team," commented Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. "He joins Alaunos at an exciting time as we continue to advance development of our promising TCR T Library

    8/4/22 5:00:00 PM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TCRT
    Financials

    Live finance-specific insights

    View All

    Alaunos Therapeutics Reports First Quarter 2023 Financial Results

    Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023Fully prepaid loan with Silicon Valley Bank; now a debt-free companyAmended exclusive licensing agreement with Precigen, Inc., reflecting the Company's focus on its TCR-T programs and eliminating long-term financial obligationsCompany to host conference call today at 9:00 a.m. ET HOUSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announce

    5/10/23 7:00:17 AM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

    HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 9:00 a.m. ET to review the financial results and provide a corporate update. Register for the live webcast using the link here or by visiting the "Investors" section of the Alaunos website at www.alaunos.com. To partici

    5/3/23 8:30:00 AM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023

    HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022, on Tuesday, March 7, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to review the financial results and provide a corporate update. Register for the live webcast using the link here or by visiting the "Investors" section of the Alaunos website at www.alaunos.com. To participate via telephone, please register in advance at

    2/28/23 4:01:07 PM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TCRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Alaunos Therapeutics Inc.

    SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)

    11/14/24 4:06:27 PM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Alaunos Therapeutics Inc. (Amendment)

    SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)

    2/14/24 12:43:20 PM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Alaunos Therapeutics Inc. (Amendment)

    SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)

    2/13/24 4:58:29 PM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care